Healthcare >> Sector Roundtables >> July 8, 2002
JOSEPH P. DOUGHERTY, a Vice President at Lehman Brothers, joined the
firm in April 2000 from UBS Warburg, where he was Senior Biotechnology
Analyst. He was at UBSW and its predecessor firms for three years. Prior
to coming to the Street, he was a scientist at Gilead Sciences in
antiviral and cardiovascular medicinal chemistry and drug development,
and at Genetics Institute in DNA-based diagnostics and bioorganic
chemistry. He has an AB in Chemistry from Harvard, a PhD in Bioorganic
Chemistry from Columbia, and is the author of numerous scientific papers
and several patents. Profile
JONATHAN ASCHOFF, PhD, joined the healthcare team of Friedman, Billings,
Ramsey & Co., Inc. (FBR) as a Senior Research Analyst in March 2001.
Prior to joining the firm, Dr. Aschoff was a Senior Research Analyst at
Dain Rauscher Wessels covering genomics and had worked as a more
generalized biotech analyst at Sturza's Institutional Research, where he
covered antimicrobial and oncology therapeutics, therapeutic antibodies,
gene therapy and genomics. Dr. Aschoff received his PhD in Microbiology
and Molecular Biology and his BS in Biology from Tufts University. Profile
FRANKLIN M. BERGER is a Managing Director in the US Equity Research
Department of J. P. Morgan H & Q, having joined the firm in 1998. He is
a Senior Biotechnology Analyst and part of the Global Health Care
Research team. He received his MBA from Harvard University and both his
MA and BA degrees from Johns Hopkins University. In 2000, he became a
Founding Fellow of the Biotechnology Study Center at New York University
School of Medicine. Profile
FARIBA GHODSIAN is Managing Director and Director of Healthcare Research
at Roth Capital Partners, where she oversees the biotechnology and
medical device equity research team. She has also worked as senior
biotech analyst with other investment banking firms and held positions
of research scientist, director of business development, acting CFO and
board member for biotech and pharmaceutical companies and investment
funds. She has an MBA from UCLA (Beta Gamma Sigma), postdoctoral
fellowship from Harvard Medical School, PhD in Biomedical Engineering
from Oxford University, MS from MIT and BS from Technion, Israel
Institute of Technology, both in Chemical Engineering. Profile
Craig D. West is an Associate Vice President and Senior Biotech Analyst
at A.G. Edwards & Sons. He specializes in biotechnology, genomics and
gene therapy firms involved in the human medical area. He previously
worked at Genentech, Inc., and California Public Employees Retirement
System. He holds an MS in Biochemistry and an MBA from the University of
California, Davis, and a BS in Molecular and Cell Biology, magna cum
laude, from the University of Connecticut. Profile
ALEXANDER A. HITTLE, CFA, is a Senior Research Analyst at A.G. Edwards
where he covers biotechnology and genomics firms. He previously worked
as a lobbyist for a non-profit environmental organization in Washington,
DC. He has an MA from the Johns Hopkins School of Advanced
International Studies (SAIS) and a BA from Brown University. He
currently serves as the Chair of the Board of Bloom, a non-profit
organization dedicated to bringing state-of-the-art IT to institutions
involved in plant conservation. Profile
stocks performed year to date 2002?
Mr. West: They've performed terribly. We've subdivided the sector into
gene therapy,
